Reuters logo
BRIEF-Aclaris initiates phase 1 clinical trial for ati-50001
December 7, 2016 / 1:35 PM / 10 months ago

BRIEF-Aclaris initiates phase 1 clinical trial for ati-50001

Dec 7 (Reuters) - Aclaris Therapeutics Inc -

* Trial is being conducted in 12 healthy volunteers to evaluate safety, bioavailability, and pharmacodynamics of ATI-50001

* Aclaris Therapeutics initiates phase 1 clinical trial for ATI-50001, an investigational JAK inhibitor, for the treatment of alopecia totalis and alopecia universalis Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below